SPRO [NASD]
Spero Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.48 Insider Own1.10% Shs Outstand32.98M Perf Week1.52%
Market Cap78.28M Forward P/E- EPS next Y-1.33 Insider Trans-81.27% Shs Float29.54M Perf Month147.86%
Income-113.30M PEG- EPS next Q-0.25 Inst Own57.90% Short Float2.63% Perf Quarter141.72%
Sales9.90M P/S7.91 EPS this Y17.50% Inst Trans0.69% Short Ratio0.11 Perf Half Y-77.01%
Book/sh1.09 P/B1.83 EPS next Y43.40% ROA-86.30% Target Price11.25 Perf Year-89.14%
Cash/sh1.16 P/C1.72 EPS next 5Y36.90% ROE-151.80% 52W Range0.68 - 18.84 Perf YTD-87.51%
Dividend- P/FCF- EPS past 5Y-6.20% ROI-64.40% 52W High-89.38% Beta1.18
Dividend %- Quick Ratio3.70 Sales past 5Y122.50% Gross Margin- 52W Low194.07% ATR0.30
Employees41 Current Ratio3.70 Sales Q/Q-60.80% Oper. Margin- RSI (14)66.96 Volatility12.46% 21.31%
OptionableYes Debt/Eq0.00 EPS Q/Q-39.00% Profit Margin- Rel Volume0.32 Prev Close1.97
ShortableNo LT Debt/Eq0.00 EarningsAug 10 AMC Payout- Avg Volume7.29M Price2.00
Recom2.20 SMA2052.81% SMA5094.48% SMA200-62.26% Volume2,311,183 Change1.52%
Sep-23-22Upgrade Evercore ISI In-line → Outperform $2 → $8
Oct-01-21Downgrade Oppenheimer Outperform → Perform
Jan-22-21Reiterated H.C. Wainwright Buy $33 → $40
Dec-16-20Initiated Berenberg Buy $47
Sep-29-20Initiated Evercore ISI Outperform
Nov-05-19Reiterated H.C. Wainwright Buy $28 → $35
Sep-09-19Initiated Janney Buy
Feb-09-18Initiated Cantor Fitzgerald Overweight $27
Nov-27-17Initiated Stifel Buy $26
Nov-27-17Initiated Oppenheimer Outperform $30
Nov-27-17Initiated BofA/Merrill Neutral $16
Sep-25-22 07:00AM
Sep-23-22 11:02AM
Sep-22-22 11:30AM
10:53AM
07:20AM
02:00AM Loading…
02:00AM
Sep-15-22 04:05PM
Sep-07-22 12:37PM
10:36AM
08:05AM
Sep-06-22 10:10AM
08:05AM
Sep-05-22 06:49AM
Aug-25-22 09:55AM
Aug-10-22 05:25PM
04:05PM Loading…
04:05PM
Aug-09-22 08:05AM
Jul-06-22 02:30AM
Jun-27-22 04:27PM
04:05PM
May-31-22 07:30AM
May-16-22 05:35PM
04:05PM
May-11-22 08:05AM
May-09-22 08:05AM
May-04-22 09:15AM
May-03-22 05:29PM
12:41PM
09:59AM
08:23AM
07:05AM Loading…
07:05AM
Apr-28-22 03:02PM
Apr-21-22 08:05AM
Apr-06-22 05:31PM
Mar-31-22 05:55PM
04:05PM
Mar-29-22 10:39AM
Mar-28-22 06:51PM
Mar-17-22 08:05AM
Feb-16-22 08:05AM
Feb-10-22 10:47AM
Jan-20-22 05:36AM
Jan-19-22 08:05AM
Jan-04-22 11:38AM
08:48AM
08:05AM
Jan-03-22 08:05AM
05:03AM
Dec-28-21 02:38AM
Nov-17-21 08:05AM
Nov-12-21 11:06AM
Nov-10-21 05:45PM
04:05PM
Nov-03-21 08:05AM
Oct-28-21 03:05PM
08:05AM
Oct-12-21 08:05AM
Oct-05-21 07:11AM
Oct-01-21 04:01PM
Sep-30-21 03:00PM
08:00AM
Sep-28-21 12:45PM
Sep-16-21 08:05AM
Sep-07-21 08:05AM
Sep-02-21 08:46AM
Aug-31-21 04:25PM
12:00PM
Aug-11-21 02:07AM
Aug-10-21 06:47AM
Aug-05-21 05:55PM
04:01PM
Jul-30-21 04:33PM
Jul-29-21 04:01PM
03:05PM
Jul-07-21 04:01PM
12:56PM
Jul-06-21 01:00PM
Jul-05-21 06:04AM
Jul-02-21 04:01PM
Jul-01-21 01:12PM
Jun-30-21 06:46PM
Jun-15-21 04:01PM
Jun-11-21 07:48AM
Jun-07-21 01:41PM
May-28-21 05:35PM
May-17-21 04:01PM
May-13-21 08:00AM
May-06-21 06:05PM
04:01PM
02:30PM
Apr-30-21 04:26PM
Apr-29-21 04:01PM
Mar-31-21 04:31PM
Mar-11-21 05:45PM
04:07PM
02:30PM
Mar-09-21 05:31AM
Mar-08-21 12:30PM
Mar-03-21 08:30AM
Feb-25-21 08:30AM
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aquilo Capital Management, LLC10% OwnerSep 22Sale2.251,901,7964,279,6123,419,435Sep 26 03:32 PM
Shukla SathChief Financial OfficerAug 29Sale0.896,0175,37856,064Aug 30 05:00 PM
Aquilo Capital Management, LLC10% OwnerApr 26Buy5.2439,727207,9715,321,231Apr 28 04:13 PM
Aquilo Capital Management, LLC10% OwnerMar 30Buy8.7950,000439,4205,281,504Mar 31 03:51 PM
Aquilo Capital Management, LLC10% OwnerMar 14Buy7.6323,708180,7975,231,504Mar 16 04:23 PM
Aquilo Capital Management, LLC10% OwnerFeb 28Buy9.5344,833427,2275,207,796Mar 02 03:52 PM
Aquilo Capital Management, LLC10% OwnerFeb 18Buy9.2414,828137,0395,162,963Feb 23 04:24 PM
Aquilo Capital Management, LLC10% OwnerJan 31Buy11.59125,0001,448,2625,148,135Feb 01 08:26 PM
Aquilo Capital Management, LLC10% OwnerJan 24Buy10.891,59917,4185,023,135Jan 26 05:12 PM
Aquilo Capital Management, LLC10% OwnerJan 18Buy12.4148,488601,9645,021,536Jan 20 01:07 PM
Aquilo Capital Management, LLC10% OwnerJan 10Buy12.938,867114,6094,973,048Jan 12 04:43 PM
Aquilo Capital Management, LLC10% OwnerDec 31Buy15.75125,0001,969,0254,964,181Jan 03 02:46 PM
Aquilo Capital Management, LLC10% OwnerDec 30Buy15.7750,000788,6104,839,181Jan 03 02:46 PM
Aquilo Capital Management, LLC10% OwnerDec 29Buy14.6475,4931,105,2634,789,181Jan 03 02:46 PM
Mahadevia AnkitCEO and PresidentDec 27Option Exercise5.908,00047,200152,036Dec 29 06:26 PM
Mahadevia AnkitCEO and PresidentDec 27Sale14.588,000116,666144,036Dec 29 06:26 PM
Aquilo Capital Management, LLC10% OwnerOct 29Buy17.53150,0002,630,1754,713,688Nov 02 05:47 PM